• Home
  • News
  • Tag - 
  • Astrocyte Pharmaceuticals

Tag - Astrocyte Pharmaceuticals

19Jul

Drug for concussion, stroke found by UT scientist moves closer to human trials

Astrocyte Pharmaceuticals, the company Lechleiter founded with William Korinek of Boston, completed Monday its first round of financing that raised roughly $2.4 million in fresh capital. The fledgling company had $670,000 in seed funding from the federal government since 2014. Lechleiter hopes the drug, which is at least 7 years away from market, could be easily administered by any football coach or paramedic to mitigate the effects of concussions or strokes. Read more >>
Portfolio News
Read more...
28Mar

Boston Harbor Angels Bet on New Frontier in Neuroscience

Boston Harbor Angels has invested in two neuroscience startups targeting stroke, TBI and Parkinson's Disease, leading a $1.3M angel seed round in Astrocyte Pharmaceuticals and members investing in Neuraly. Astrocyte Pharmaceuticals Inc. is a privately held drug development company dedicated to accelerating the recovery and well-being of brain injury patients. The company is committed to proving the neuroprotective benefits of selective astrocyte activation, and advancing breakthrough therapeutic agents for treating brain injury resulting from stroke, TBI, concussion, and neurodegenerative disorders such...
Organization News, Portfolio News, Press Release,
Read more...
25Mar

Astrocyte Pharmaceuticals Raises Over $1.3M in Seed Financing Round

Astrocyte Pharmaceuticals Inc., a CNS therapeutics startup, announced today that it has raised approximately $1.36M in a seed financing round. The company is developing novel small molecule drugs that limit neuronal damage in patients that have suffered a stroke, traumatic brain injury (TBI) or concussion. The seed financing round was led by Boston Harbor Angels, and joined by the University of Texas Horizon Fund, SideCar Angels and others. Read more >>
Organization News, Portfolio News
Read more...